Source comparison
CJC-1295 Results After 1 Week: [Compound Type] Comparison
CJC-1295 (with DAC) Improved sleep quality, subtle recovery enhancement, occasional mild water retention GHRH receptor activation → GH pulse → IGF-1 elevation over 6–8 days No measurable body composition change; hormonal priming phase only Extended half-life m
This comparison does not assign a generated winner or score.
- CJC-1295 (with DAC)
- Improved sleep quality, subtle recovery enhancement, occasional mild water retention
- GHRH receptor activation → GH pulse → IGF-1 elevation over 6–8 days
- No measurable body composition change; hormonal priming phase only
- Extended half-life makes this ideal for twice-weekly protocols, but patience is mandatory. Week one is biochemical setup, not physical outcome
- CJC-1295 (no DAC) / Modified GRF 1-29
- Similar sleep and recovery effects but requires multiple daily doses to maintain
- Shorter half-life (30 min) requires 2–3× daily dosing to sustain GH pulses
- Identical tissue timeline as DAC version despite faster clearance
- More flexible dosing control but higher injection frequency; results timeline unchanged
- Ipamorelin
- Minimal week-one effects; cleaner GH pulse without cortisol/prolactin spike
- GHRP receptor agonism; does not elevate cortisol or prolactin like GHRP-2/6
- Body composition changes require 4+ weeks like CJC-1295
- Often stacked with CJC-1295 for synergistic effect; see CJC1295 Ipamorelin 5MG 5MG for combined research applications
- MK-677 (Ibutamoren)
- Increased appetite within 48–72 hours; mild water retention; improved sleep
- Oral ghrelin mimetic; stimulates GH release through ghrelin receptor activation
- Fat loss and muscle gain require 6–8 weeks minimum
- Non-peptide alternative with longer half-life (24 hours); appetite stimulation can interfere with fat loss goals in some subjects